IDYA.NASDAQIdeaya Biosciences, INC
DEF: IDEAYA Biosciences Sets Date for 2025 Annual Stockholders Meeting
Sentiment:
Proxy Statement
IDEAYA Biosciences will hold its 2025 Annual Meeting of Stockholders online on June 24, 2025, to vote on director elections, auditor ratification, and executive compensation.
Summary
- IDEAYA Biosciences will hold its Annual Meeting of Stockholders online on June 24, 2025.
- Stockholders as of the record date, April 28, 2025, are eligible to vote.
- The meeting will address the election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
- The Board recommends voting for the director nominees, for the ratification of PricewaterhouseCoopers LLP, and for the approval of executive compensation.
- The company's common stock outstanding as of the Record Date was 87,577,550 shares.
- The Board is divided into three classes, with Class III directors serving until the 2028 annual meeting.
- PricewaterhouseCoopers LLP has served as the company's independent accounting firm since the fiscal year ended December 31, 2017.
- The company's Code of Business Conduct and Ethics, Corporate Governance Guidelines, and committee charters are available on its website.
- The company's policy prohibits directors, officers, and employees from hedging or pledging IDEAYA securities.
- The company's executive compensation program includes base salary, annual performance-based bonuses, and long-term equity-based incentives.
- The company's CEO's total compensation for 2024 was approximately 36 times the median of the annual total compensation of all of its other employees.
- The company's equity compensation plans include the 2019 Incentive Award Plan, the Employee Stock Purchase Plan, and the 2015 Equity Incentive Plan.
- The company's largest stockholders include FMR LLC (14.4%), BlackRock, Inc. (8.1%), and Janus Henderson Group plc (6.7%).
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions. The sentiment is slightly positive due to the routine nature of the activities and the absence of any explicitly negative information.
Positives
- The Board recommends voting for the director nominees, for the ratification of PricewaterhouseCoopers LLP, and for the approval of executive compensation.
- The company has a Code of Business Conduct and Ethics, Corporate Governance Guidelines, and committee charters available on its website, indicating a commitment to corporate governance.
- The company's executive compensation program is designed to align executive interests with those of stockholders through equity-based compensation.
- The company's 401(k) plan includes employer matching contributions, which incentivizes employees, including executives.
- The company's largest stockholders include FMR LLC (14.4%), BlackRock, Inc. (8.1%), and Janus Henderson Group plc (6.7%).
Negatives
- The company's CEO's total compensation for 2024 was approximately 36 times the median of the annual total compensation of all of its other employees.
Risks
- The document does not explicitly detail any specific risks, but general business risks are inherent in the company's operations and industry.
Future Outlook
The document outlines the proposals to be voted on at the 2025 Annual Meeting of Stockholders, including the election of directors, ratification of the independent accounting firm, and approval of executive compensation, setting the stage for the company's governance and strategic direction.
Management Comments
- On behalf of the Board of Directors, I would like to express our appreciation for your interest in IDEAYA.
Industry Context
This announcement is typical for publicly traded companies, providing stockholders with the necessary information to make informed decisions regarding the company's direction and governance.
Comparison to Industry Standards
- The peer group was selected by considering publicly-traded, pre-commercial biopharma companies, with a focus on oncology, in the San Francisco/Bay Area, Boston/Cambridge area and other biotech hub locations, with market cap between $500 million and $5.0 billion, based on IDEAYAs market capitalization of approximately $1.5 billion at the time, and headcount between 40 and 400 employees, based on IDEAYAs headcount of 127 employees at the time.
- At the time the 2024 Peer Group was approved, our company fell at the 54th percentile based on market capitalization of the 2024 Peer Group and 32 nd percentile based on headcount2024 Peer Group.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Legal Officer and Corporate Secretary | Jason S. Throne | NA | July 11, 2024 | Voluntary resignation |
| Chief Accounting Officer | NA | Andres Ruiz Briseno | March 1, 2025 | Appointment |
| Chief Financial Officer | NA | Joshua Bleharski, Ph.D. | May 2025 | Appointment |
Stakeholder Impact
- Stockholders are provided with information to make informed decisions regarding the company's governance and strategic direction.
- Employees are subject to a Code of Business Conduct and Ethics.
- Directors and officers are subject to policies regarding insider trading and hedging.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will announce the voting results within four business days after the Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 2015 | Jeffrey L. Stein, Ph.D. has served as a member of our board of directors since October 2015. |
| 2017-12-31 | PwC has audited our financial statements for each of our fiscal years since the fiscal year ended December 31, 2017. |
| 2018 | Scott W. Morrison has served as a member of our board of directors since July 2018. |
| 2019 | Wendy L. Yarno has served as a member of our board of directors since December 2019. |
| 2020 | M. Garret Hampton, Ph.D . has served as a member of our board of directors since June 2020. |
| 2022 | Catherine J. Mackey, Ph.D. has served as a member of our board of directors since April 2022. |
| 2023 | Terry J. Rosen, Ph.D. has served as chairperson of our board of directors since June 2023. |
| 2024-01-01 | Transactions and series of similar transactions, since January 1, 2024 or entered into prior to January 1, 2024 which have continuing obligations to which we were a party in which: the amounts involved exceeded or will exceed $120,000; and any of our directors, executive officers or holders of more than 5% of our common stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. |
| 2024-12-31 | The following table sets forth the compensation awarded to, earned by or paid to our non-employee directors who served on our Board during the year ended December 31, 2024. |
| 2025-04-28 | Only stockholders who owned common stock of the Company at the close of business on April 28, 2025 (the Record Date) can vote at this meeting or any adjournments that take place. |
| 2025-04-30 | South San Francisco, California April 30, 2025 |
| 2025-05-15 | We will begin mailing the Notice of Annual Meeting of Stockholders, this Proxy Statement, proxy card and our Annual Report on Form 10-K to our stockholders of record as of April 28, 2025 (the Record Date) for the first time on or about May 15, 2025. |
| 2025-06-24 | The Annual Meeting will be held on Tuesday, June 24, 2025, at 10:00 a.m. Pacific Time. |
| 2025-12-31 | To be considered for inclusion in next years proxy materials, your proposal must be submitted in writing by December 31, 2025 |
| 2026-02-24 | Pursuant to the bylaws, in order for a stockholder to present a proposal for next years annual meeting, other than proposals to be included in the proxy statement as described above, or to nominate a director, you must do so between February 24, 2026 and March 26, 2026 |
| 2026-03-26 | Pursuant to the bylaws, in order for a stockholder to present a proposal for next years annual meeting, other than proposals to be included in the proxy statement as described above, or to nominate a director, you must do so between February 24, 2026 and March 26, 2026 |
| 2026-04-25 | In addition to satisfying the foregoing requirements under the Companys bylaws, to comply with the universal proxy rules (once they become effective), stockholders who intend to solicit proxies in support of director nominees other than the Companys nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 25, 2026. |
Keywords
stockholders, directors, compensation, governance, IDEAYA, proxy, meeting, audit, officers, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.